- ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
-
The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.
- -
-
-
- BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS
-
The invention provides compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR and erbB2 activity, as well as methods for using such compounds to treat cancer associated with mutant EGFR and erbB2 activity.
- -
-
-
- [1,3]DIAZINO[5,4-D]PYRIMIDINES AS HER2 INHIBITORS
-
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
- -
-
Page/Page column 34
(2021/08/13)
-